Skip to main content
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1996 May;74(5):437–440. doi: 10.1136/adc.74.5.437

Final height of patients who underwent bone marrow transplantation during childhood.

A Cohen 1, A Rovelli 1, M T Van-Lint 1, C Uderzo 1, A Morchio 1, C Pezzini 1, G Masera 1, A Bacigalupo 1, C Romano 1
PMCID: PMC1511535  PMID: 8669961

Abstract

OBJECTIVE: To determine the impact on final adult height of bone marrow transplantation. METHODS: The final height of 28 long term survivors (18 males; 10 females), allografted before or at the onset of puberty, at a median age of 10.8 years (range 6.3 to 14.6) and who did not receive growth hormone (GH) treatment or other growth promoting agents, was evaluated. Median follow up period after bone marrow transplantation was 7.9 years (range 3.2 to 11.4), and age at the most recent evaluation 18.1 years (range 15.6 to 24.5). Height values were expressed in standard deviation score (SDS) from the mean of the normal population. Height at bone marrow transplantation was compared with final height as well as with parental genetic height. Patients were divided into three groups: severe aplastic anaemia (SAA): three patients given no radiotherapy; leukaemia-total body irradiation (TBI): 14 patients with acute or chronic leukaemia conditioned with chemotherapy and TBI; leukaemia-TBI with previous cranial radiation therapy (CRT): 11 patients. None of the patients had solid tumour. RESULTS: There was a decrease in final height SDS compared to pre-transplantation height SDS (paired t test, p < 0.0001). All patients except one reached an adult height above -2.0 SDS. A significant decrease in height SDS was found in the TBI and the CRT groups (paired t test, p = 0.02 and p = 0.0002, respectively). Whereas height SDS value at the time of transplant was higher than the genetic height SDS, final height SDS values were lower. CONCLUSIONS: Despite the decrease in height SDS found after bone marrow transplantation, 27 of the 28 patients spontaneously achieved what is considered to be a normal height SDS (above -2.0 SDS). This should be taken into account when considering GH treatment in children who underwent bone marrow transplantation for malignant haematological diseases.

Full text

PDF
440

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blatt J. Growth hormone and leukemia. Pediatr Hematol Oncol. 1993 Jan-Mar;10(1):3–5. doi: 10.3109/08880019309016521. [DOI] [PubMed] [Google Scholar]
  2. Bozzola M., Giorgiani G., Locatelli F., Cisternino M., Gambarana D., Zecca M., Torcetta F., Severi F. Growth in children after bone marrow transplantation. Horm Res. 1993;39(3-4):122–126. doi: 10.1159/000182711. [DOI] [PubMed] [Google Scholar]
  3. Cohen A., van Lint M. T., Uderzo C., Rovelli A., Lavagetto A., Vitale V., Morchio A., Locasciulli A., Bacigalupo A., Romano C. Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood. Bone Marrow Transplant. 1995 Mar;15(3):343–348. [PubMed] [Google Scholar]
  4. Dacou-Voutetakis C., Kitra V., Grafakos S., Polychronopoulou S., Drakopoulou M., Haidas S. Auxologic data and hormonal profile in long-term survivors of childhood acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1993 Aug;15(3):277–283. [PubMed] [Google Scholar]
  5. Davies H. A., Didcock E., Didi M., Ogilvy-Stuart A., Wales J. K., Shalet S. M. Disproportionate short stature after cranial irradiation and combination chemotherapy for leukaemia. Arch Dis Child. 1994 Jun;70(6):472–475. doi: 10.1136/adc.70.6.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dickerman Z., Cohen A., Laron Z. Growth in patients with isolated gonadotrophin deficiency. Arch Dis Child. 1992 Apr;67(4):513–516. doi: 10.1136/adc.67.4.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Estrov Z., Meir R., Barak Y., Zaizov R., Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol. 1991 Mar;9(3):394–399. doi: 10.1200/JCO.1991.9.3.394. [DOI] [PubMed] [Google Scholar]
  8. Fradkin J. E., Mills J. L., Schonberger L. B., Wysowski D. K., Thomson R., Durako S. J., Robison L. L. Risk of leukemia after treatment with pituitary growth hormone. JAMA. 1993 Dec 15;270(23):2829–2832. [PubMed] [Google Scholar]
  9. Hovi L., Rajantie J., Perkkiö M., Sainio K., Sipilä I., Siimes M. A. Growth failure and growth hormone deficiency in children after bone marrow transplantation for leukemia. Bone Marrow Transplant. 1990 Mar;5(3):183–186. [PubMed] [Google Scholar]
  10. Olshan J. S., Willi S. M., Gruccio D., Moshang T., Jr Growth hormone function and treatment following bone marrow transplant for neuroblastoma. Bone Marrow Transplant. 1993 Oct;12(4):381–385. [PubMed] [Google Scholar]
  11. Sanders J. E., Pritchard S., Mahoney P., Amos D., Buckner C. D., Witherspoon R. P., Deeg H. J., Doney K. C., Sullivan K. M., Appelbaum F. R. Growth and development following marrow transplantation for leukemia. Blood. 1986 Nov;68(5):1129–1135. [PubMed] [Google Scholar]
  12. Shinohara O., Kato S., Yabe H., Yabe M., Kubota C., Mitsuda R., Kimura M. Growth after bone marrow transplantation in children. Am J Pediatr Hematol Oncol. 1991 Fall;13(3):263–268. doi: 10.1097/00043426-199123000-00003. [DOI] [PubMed] [Google Scholar]
  13. Shulman H. M., Sullivan K. M., Weiden P. L., McDonald G. B., Striker G. E., Sale G. E., Hackman R., Tsoi M. S., Storb R., Thomas E. D. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980 Aug;69(2):204–217. doi: 10.1016/0002-9343(80)90380-0. [DOI] [PubMed] [Google Scholar]
  14. Sklar C., Mertens A., Walter A., Mitchell D., Nesbit M., O'Leary M., Hutchinson R., Meadows A., Robison L. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr. 1993 Jul;123(1):59–64. doi: 10.1016/s0022-3476(05)81537-9. [DOI] [PubMed] [Google Scholar]
  15. Tanner J. M., Goldstein H., Whitehouse R. H. Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child. 1970 Dec;45(244):755–762. doi: 10.1136/adc.45.244.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Willi S. M., Cooke K., Goldwein J., August C. S., Olshan J. S., Moshang T., Jr Growth in children after bone marrow transplantation for advanced neuroblastoma compared with growth after transplantation for leukemia or aplastic anemia. J Pediatr. 1992 May;120(5):726–732. doi: 10.1016/s0022-3476(05)80235-5. [DOI] [PubMed] [Google Scholar]
  17. Wingard J. R., Plotnick L. P., Freemer C. S., Zahurak M., Piantadosi S., Miller D. F., Vriesendorp H. M., Yeager A. M., Santos G. W. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood. 1992 Feb 15;79(4):1068–1073. [PubMed] [Google Scholar]
  18. Yamada S., Ishii E., Okabe Y., Kai T., Kuroiwa T., Hasuo K., Akazawa K., Tasaka H., Ueda K. Growth retardation in childhood leukemia and lymphoma. Special reference to patients with CNS relapse. Am J Pediatr Hematol Oncol. 1992 Aug;14(3):236–240. doi: 10.1097/00043426-199208000-00010. [DOI] [PubMed] [Google Scholar]
  19. Zurlo M. G., Senesi E., Terracini B., Balducci D., Biddau P., D'Angelo P., Rosati D., Gandus S., Madon E., Mancini A. Height of children off therapy after acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1988;5(3):187–195. doi: 10.3109/08880018809031269. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES